{"id":"W2116137820","doi":"10.3747/co.22.2431","title":"An Open-Label Expanded-Access Trial of Bendamustine in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma or Previously Untreated Chronic Lymphocytic Leukemia: BEND-ACT","year":2015,"lang":"en","type":"article","venue":"Current Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency; University of Manitoba; University of Calgary; Hôpital de l'Enfant-Jésus; Dalhousie University; University of Toronto; McMaster University; Université du Québec à Montréal; Juravinski Cancer Centre","funders":"National Cancer Institute; Lundbeck Canada","keywords":"Bendamustine; Medicine; Tolerability; Neutropenia; Rituximab; Internal medicine; Chronic lymphocytic leukemia; Adverse effect; Nausea; Refractory (planetary science); Oncology; Lymphoma; Leukemia; Chemotherapy","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":true,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001135189,0.0006349921,0.00198813,0.0006383821,0.00008520312,0.00008834434,0.001397657,0.0005042957,0.0002498683],"category_scores_gemma":[0.0006115381,0.0004643842,0.0000766786,0.001135202,0.0005270908,0.0007211803,0.0008353306,0.0005478703,0.00005547607],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.1744912,"about_ca_system_score_gemma":0.1470286,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003262511,"about_ca_topic_score_gemma":0.00174171,"domain_scores_codex":[0.9944111,0.0005506448,0.001403222,0.001134914,0.001231232,0.001268861],"domain_scores_gemma":[0.9958624,0.0003565298,0.0007105832,0.001314891,0.000816737,0.0009389119],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5517793,0.03151861,0.02229714,0.001478484,0.000443298,0.0008469356,0.002093205,0.0004567101,0.0001845172,0.00002205876,0.003489834,0.3853899],"study_design_scores_gemma":[0.8983859,0.07145677,0.00903932,0.00109399,0.0003087818,0.0001234179,0.0001467354,0.0130714,0.0005886481,0.00001548882,0.005223811,0.0005457143],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9915164,0.0008338321,0.00004508822,0.00003912724,0.001102784,0.005545056,0.00005067018,0.00008604595,0.0007809605],"genre_scores_gemma":[0.9974469,0.0003693069,0.0002250465,0.00007139955,0.0004896059,0.000579351,0.0005680608,0.0001177231,0.0001325988],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3848442,"threshold_uncertainty_score":0.9997808,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1706744940988884,"score_gpt":0.4602888018471838,"score_spread":0.2896143077482954,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}